Principal Solutions Consultant
Model N- Full Time
- Junior (1 to 2 years)
Candidates should possess 7+ years of experience in a customer-facing role, with at least 2+ years of experience in a technical pre-sales sales role selling to large enterprises. They should demonstrate a strong desire to leverage consultative selling skills and develop in-depth knowledge of the company’s technology and market, particularly within the rapidly evolving field of AI. Furthermore, candidates must be able to interact with a wide range of stakeholders, including C-level executives and end users, utilizing a consultative selling approach.
The Director, Client Solutions will solve problems for potential customers by understanding their situation and challenges, showcasing the value of Manifold’s AI-powered clinical research platform, and crafting solutions using the product suite. They will build trusted, consultative relationships with stakeholders, deliver captivating product demos, collaborate with Sales and Marketing teams, provide insights and learnings, drive adoption during proof of value, translate use cases into technical solutions, and provide feedback to product management. Additionally, they will assist in post-sales implementation activities as needed.
Designs precision biologics using in vivo methods
Manifold Bio specializes in creating precision biologics for the pharmaceutical industry, focusing on drug design and development. Their main product is an in vivo drug design platform, which allows for testing drugs within living organisms rather than in laboratory settings. This platform utilizes mCodes™ technology, a unique protein barcoding system that enables the simultaneous study of multiple proteins in one experiment, making it particularly effective for complex biologics. Unlike other companies, Manifold Bio's approach to drug design is distinct because it integrates in vivo testing with advanced protein multiplexing capabilities. The company's goal is to expand their platform and collaborate with other pharmaceutical companies to develop new therapeutics.